Calliditas Therapeutics AB (publ) (CALT) News Today → Your Portfolio’s Shield Against Inflation: Gold’s Surge and AI Breakthroughs (From InvestorPlace) (Ad) Free CALT Stock Alerts $21.00 +0.46 (+2.24%) (As of 10:39 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineWhat Wall Street expects from Calliditas Therapeutics (spons ADRs)'s earningsmarkets.businessinsider.com - May 6 at 9:49 PMCalliditas releases phase 2 results on head and neck cancer asset setanaxibmsn.com - May 6 at 4:48 PMCalliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibprnewswire.com - May 6 at 2:11 AMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $18.65marketbeat.com - April 30 at 1:05 PMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Price Down 9.3%marketbeat.com - April 29 at 4:36 PMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Up 121.9% in Aprilmarketbeat.com - April 26 at 9:13 PMCalliditas Therapeutics' 2023 Annual Report Publishedfinance.yahoo.com - April 24 at 4:21 PMCalliditas Announces Positive NefIgArd Open Label Extension Resultsprnewswire.com - April 24 at 3:26 AMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Down 6.4%marketbeat.com - April 22 at 2:54 PMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading 3.4% Higher marketbeat.com - April 19 at 12:24 PMLatest News for Calliditas Therapeutics Stock (NASDAQ:CALT)benzinga.com - April 19 at 9:04 AMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $18.74marketbeat.com - April 18 at 1:56 PMCalliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024prnewswire.com - April 18 at 7:10 AMBuy Rating Affirmed for Calliditas Therapeutics Amid Positive Market Trends and Upcoming Catalystsmarkets.businessinsider.com - April 11 at 6:57 PMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Down 56.2% in Marchmarketbeat.com - April 11 at 5:23 PMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Price Down 8.3%marketbeat.com - April 10 at 12:57 PMCalliditas Therapeutics to Attend Conferences in Aprilfinance.yahoo.com - April 9 at 9:13 AMCalliditas Therapeutics to Attend Conferences in Aprilprnewswire.com - April 9 at 7:22 AMCalliditas Gets Notice Of Allowance For U.S. Patent Application Covering Setanaxib To Treat Cancermarkets.businessinsider.com - April 8 at 10:32 AMCalliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Airesprnewswire.com - April 8 at 8:32 AMCalliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatmentprnewswire.com - April 8 at 3:22 AMCalliditas Therapeutics AB Sponsored ADRcnn.com - April 7 at 2:38 AMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $21.25marketbeat.com - April 4 at 1:20 PMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Up 4.5%marketbeat.com - April 1 at 3:29 PMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Significant Growth in Short Interestmarketbeat.com - March 31 at 10:34 PMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $21.49marketbeat.com - March 28 at 7:27 PMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Price Down 3.8%marketbeat.com - March 26 at 5:46 PMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Down 7.2% marketbeat.com - March 19 at 4:49 PMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $22.30marketbeat.com - March 18 at 11:23 AMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Large Increase in Short Interestmarketbeat.com - March 14 at 7:52 PMEverest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®prnewswire.com - March 11 at 9:28 PMCalliditas Therapeutics: Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYOfinanznachrichten.de - March 6 at 9:24 PMCalliditas Therapeutics: Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®finanznachrichten.de - March 6 at 4:23 PMCalliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®prnewswire.com - March 6 at 2:34 AMCalliditas Therapeutics to Attend Investor Conferences in Marchprnewswire.com - March 1 at 7:39 AMFulcrum Therapeutics Q4 2023 Earnings Previewmsn.com - February 26 at 12:56 PMCalliditas Therapeutics AB (CALT) Price Target Increased by 5.27% to 42.86msn.com - February 25 at 10:38 AMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 22 at 12:53 PMCalliditas Therapeutics: Strong Sales and FDA Approval Propel Buy Ratingmarkets.businessinsider.com - February 22 at 7:53 AMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Strong Trading Volumemarketbeat.com - February 21 at 11:27 AMCalliditas Year-end report, January - December 2023prnewswire.com - February 21 at 1:43 AMInvitation to the presentation of Calliditas´ Year-end report January - December 2023finance.yahoo.com - February 14 at 3:49 AMInvitation to the presentation of Calliditas´ Year-end report January - December 2023prnewswire.com - February 14 at 1:09 AMAN2 Therapeutics extends losses as Leerink cuts on trial setbackmsn.com - February 13 at 12:46 PMCalliditas provides patent updatefinance.yahoo.com - February 13 at 12:46 PMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Up 9.4%marketbeat.com - February 6 at 4:30 PMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Updatemarketbeat.com - January 26 at 10:35 PMCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Up 20.0% in Decembermarketbeat.com - January 14 at 2:30 PMCalliditas Therapeutics provides business update ahead of JP Morgan conferencefinance.yahoo.com - January 8 at 9:25 AMCalliditas to present at JP Morgan Healthcare Conferencefinance.yahoo.com - January 7 at 1:30 PM Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better. Click here to find out that this 8,788% cryptocurrency is. CALT Media Mentions By Week CALT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CALT News Sentiment▼0.320.58▲Average Medical News Sentiment CALT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CALT Articles This Week▼52▲CALT Articles Average Week Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Stoke Therapeutics News GH Research News Olema Pharmaceuticals News Phathom Pharmaceuticals News Zymeworks News Pharming Group News IGM Biosciences News Lyell Immunopharma News ORIC Pharmaceuticals News ArriVent BioPharma News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CALT) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersTrump is sounding the alarmPreserve GoldThis 1 Biotech Stock has been shocking the marketsHuge AlertsNext President (Not Trump. Not Biden.)The Freeport SocietyThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
